Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

Alfuzosin Hydrochloride to Relieve Ureteral Stent Discomfort

To assess the impact of alfuzosin vs. placebo on ureteral stent discomfort, urinary symptoms and quality of life.

Inclusion Criteria:

• Age >18
• Undergoing unilateral retrograde ureteroscopy with ureteral stent placement

Exclusion Criteria:

• Significant ureteral trauma
• Concomitant ESWL or other secondary surgical procedure than may impact patient comfort
• Subject with know hypersensitivity to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets.
• Pregnancy, nursing mother, or woman of child-bearing age unwilling to take contraception for the duration of the study
• Undergoing bilateral ureteral stenting
• Undergoing antegrade ureteral stenting
• Undergoing simultaneous extracorporeal shockwave lithotripsy
• Urinary infection (fever >101, positive urine culture, many bacteria on urinalysis)
• Primary bladder dysfunction that would impact ability to void without a catheter
• Neurologic dysfunction that would impair pain sensation
• History of chronic pain or substance abuse
• Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased
• Other alpha-blockers
• Phosphodiesterase type 5 inhibitors for erectile function Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study.